ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Decitabine and Cedazuridine
Drug: Enzalutamide

First Posted Date: 2021-09-08

Last Posted Date: 2024-11-14

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT05037500

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Tobacco Users Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study]

Not Applicable

Completed

Conditions: Tobacco Smoking
Tobacco Use
Cigarette Smoking
Smokeless Tobacco Cessation

Interventions: Other: Electronic Cigarette
Other: Oral Nicotine Pouch

First Posted Date: 2021-09-01

Last Posted Date: 2023-10-26

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT05030194

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Phase 2

Recruiting

Conditions: Fallopian Tube Serous Adenocarcinoma
Ovarian Clear Cell Adenocarcinoma
Primary Peritoneal Endometrioid Adenocarcinoma
Fallopian Tube Carcinosarcoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Serous Adenocarcinoma
Primary Peritoneal Carcinosarcoma
Recurrent Ovarian Carcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Ovarian Carcinosarcoma

Interventions: Procedure: Biopsy
Biological: Bevacizumab
Procedure: Biospecimen Collection
Drug: Pegcetacoplan
Other: Questionnaire Administration
Biological: Pembrolizumab

First Posted Date: 2021-06-09

Last Posted Date: 2024-06-20

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 60

Registration Number: NCT04919629

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Phase 2

Recruiting

Conditions: Plasma Cell Myeloma

Interventions: Biological: Belantamab Mafodotin
Drug: Lenalidomide

First Posted Date: 2021-05-06

Last Posted Date: 2024-11-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT04876248

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

Early Phase 1

Withdrawn

Conditions: Malignant Solid Neoplasm
Pancreatic Carcinoma
Colorectal Carcinoma
Lung Adenocarcinoma

Interventions: Drug: Binimetinib
Drug: Palbociclib
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2021-05-03

Last Posted Date: 2023-12-22

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT04870034

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Phase 1

Suspended

Conditions: Lung Non-Small Cell Carcinoma
Pleural Disorder

Interventions: Drug: Porfimer Sodium
Procedure: Video-Assisted Thoracic Surgery
Drug: Photodynamic Therapy
Device: Intraoperative PDT

First Posted Date: 2021-04-08

Last Posted Date: 2024-06-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT04836429

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study

Early Phase 1

Withdrawn

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Thermotherapy

First Posted Date: 2021-03-18

Last Posted Date: 2022-05-12

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT04803630

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

SurVaxM Expanded Access Protocol

Conditions: Glioblastoma

First Posted Date: 2021-03-17

Last Posted Date: 2021-11-16

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT04802447

Yoga Intervention for the Improvement of Cancer-Related Stress in Cancer Survivors

Not Applicable

Recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Quality-of-Life Assessment
Other: Survey Administration
Other: Yoga

First Posted Date: 2021-02-15

Last Posted Date: 2024-10-21

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT04754529

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Effects of Filter Ventilation and Ventilation Information on Product Use Behaviors in Cigarette Smokers

Not Applicable

Completed

Conditions: Cigarette Smoking-Related Carcinoma

Interventions: Other: Cigarette packaging
Other: Data capture
Other: Questionnaire administration

First Posted Date: 2021-02-08

Last Posted Date: 2023-12-26

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 115

Registration Number: NCT04744285

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy